Biotech Startups

Revelio Therapeutics is a biotechnology company developing tumor-specific biologic drugs for cancer treatment.

1 investor

Revilico builds an operating system for pharmaceutical R&D that unifies computational drug discovery tools—including molecular dynamics, quantum chemistry, generative chemistry, and virtual cell simulations—with integrated wet-lab validation. The platform serves pharmaceutical researchers and biotech companies developing small molecule drugs, covering all phases from target identification through lead optimization and preclinical development.

1 investor

Reviva Pharmaceuticals is a clinical-stage drug developer with a pipeline of two in-house-discovered new chemical entities, brilaroxazine (RP5063) and RP1208, developed using its chemical genomics platform. Its lead candidate, brilaroxazine, is being developed for schizophrenia and has completed a Phase 3 trial.

1 investor

REVO Biochem is a Canadian biotechnology company that uses fermentation science and engineered yeast to produce high-value natural compounds, aiming to build domestic bio-based ingredient supply. Its products are intended for applications across health, agriculture, and materials.

1 investor

Revolver Therapeutics develops peptide therapeutics targeting transcription factors for cancer treatment. It uses a proprietary peptide discovery and screening platform to screen millions of peptides and identify functional inhibitors.

1 investor

Rewire AI builds automated image-analysis tools for biomedical researchers, using machine learning to detect, count, and quantify cells, fluorescent probes, and biomarkers in tissue histology. Its technology serves scientists as well as biotech and digital health companies through model development and AI-layer licensing.

1 investor

Rhapsogen is developing a precision biologic therapy aimed at treating autoimmune diseases, focused on efficacy, safety, and durability.

1 investor

RheaPlant develops a plant cell bioprocessing platform designed to reduce the cost and complexity of producing botanical ingredients for nutraceuticals, natural colors, and other applications. The modular, decentralized system targets ingredient manufacturers seeking lower-cost alternatives to traditional botanical extraction and cultivation methods.

1 investor

Rhelixa provides genomic and epigenomic analysis services and consulting to life science researchers, as well as a cloud-based research support platform for medical and biological research. The company also conducts research and development related to anti-aging.

1 investor

Rheon Medical develops novel surgical devices to treat glaucoma, aiming to improve treatment efficacy and reduce post-operative complications for patients. The company is a spin-off from EPFL and combines engineering expertise with clinical guidance from ophthalmology specialists.

1 investor

Rho Bio is a biotechnology company focused on lymphatic flow, developing therapeutics related to the lymphatic system.

1 investor

RhoDx develops cell-free DNA and RNA enrichment technologies for liquid biopsy cancer diagnostics. The company provides ultra-sensitive mutation detection methods to improve the performance and accessibility of liquid biopsy testing.

1 investor

Ribogenyx develops first-in-class therapeutic enhancers of translational fidelity, targeting mRNA translation processes for precision medicine. Its focus is on age-related diseases and mechanisms of stress resilience mediated by mRNA translation.

1 investor

Stealth company developing therapeutics for undruggable targets.

1 investor

Ribo Science is a biopharmaceutical company focused on discovering and developing novel ribose-based molecules for treating human cancers and viral diseases. The company combines scientific research with technical expertise to design first-in-class therapeutic treatments.

1 investor

Riboway Therapeutics develops RNA-targeting technology powered by AI to control protein expression for therapeutic purposes. The company focuses on treating neurodegenerative and metabolic diseases, with programs including an antisense oligonucleotide targeting Spinocerebellar Ataxia Type 2.

1 investor

Rift Protein develops plant-based protein ingredients sourced from smallholder farmers in East Africa and Europe, with plans to expand into precision fermentation. The company supplies plant protein for food production using renewable energy and local processing facilities.

1 investor

RIGImmune is a biotechnology company developing stem loop RNA (SLR) therapeutics that activate the RIG-I innate immune sensor and the Type I interferon pathway for use against serious respiratory diseases. It operates a non-lipid-nanoparticle delivery platform called NEED (Nano-Emulsion Enhanced Delivery) for delivering RNA therapeutics directly to the respiratory tract.

1 investor

RIN Institute develops antibody-based pharmaceuticals and in vitro diagnostic drugs for medical research and clinical use. The company was spun out from Japan's National Cancer Center.

1 investor

Rinascera Therapeutics develops treatments for rare genetic skin diseases, with drug candidates targeting conditions such as Gorlin Syndrome and Dystrophic Epidermolysis Bullosa. It operates in the biotechnology and therapeutics sector focused on dermatological genetic disorders.

1 investor

RiverD designs and manufactures non-invasive skin analysis devices based on Raman spectroscopy technology for scientific research, clinical applications, and industrial use. The company's instruments provide precise insights into skin composition and topical product penetration.

1 investor

Rivia provides a unified clinical trial data platform that helps biotechnology companies accelerate drug development and reduce costs through technology-enabled solutions for managing complex trial operations. The platform serves biotech firms bringing new therapies to market.

1 investor

RK Pharma Inc is a US-based generic pharmaceutical group that develops, manufactures, and sells generic drugs, active pharmaceutical ingredients, and injectable, sterile ophthalmic, and dermal products, with a focus on formulation-challenged and first-generic opportunities. It operates through subsidiaries in the US and India, serving the worldwide pharmaceutical industry.

1 investor

RNA Connect develops uMRT, a reverse transcriptase enzyme for end-to-end cDNA synthesis that copies full RNA transcripts, including large viral genomes, in a single pass. The technology is aimed at gene expression, regulation, and discovery research applications in the life sciences.

1 investor